Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 08, 2022

SELL
$20.24 - $36.01 $217,984 - $387,827
-10,770 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$26.01 - $38.22 $65,051 - $95,588
2,501 Added 30.25%
10,770 $345,000
Q2 2021

Aug 13, 2021

BUY
$29.97 - $37.17 $63,296 - $78,503
2,112 Added 34.3%
8,269 $255,000
Q1 2021

May 14, 2021

SELL
$29.24 - $42.03 $20,760 - $29,841
-710 Reduced 10.34%
6,157 $207,000
Q4 2020

Feb 09, 2021

SELL
$35.35 - $50.67 $10,428 - $14,947
-295 Reduced 4.12%
6,867 $248,000
Q3 2020

Nov 13, 2020

BUY
$35.98 - $47.66 $2,950 - $3,908
82 Added 1.16%
7,162 $264,000
Q2 2020

Aug 03, 2020

BUY
$45.06 - $67.74 $48,169 - $72,414
1,069 Added 17.78%
7,080 $319,000
Q1 2020

May 15, 2020

SELL
$40.01 - $73.97 $136,874 - $253,051
-3,421 Reduced 36.27%
6,011 $285,000
Q4 2019

Feb 12, 2020

SELL
$37.13 - $74.62 $30,186 - $60,666
-813 Reduced 7.94%
9,432 $676,000
Q3 2019

Nov 12, 2019

SELL
$39.36 - $76.8 $30,858 - $60,211
-784 Reduced 7.11%
10,245 $403,000
Q2 2019

Aug 13, 2019

SELL
$52.76 - $82.19 $92,488 - $144,079
-1,753 Reduced 13.71%
11,029 $862,000
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $3,971 - $9,919
145 Added 1.15%
12,782 $762,000
Q4 2018

Feb 14, 2019

SELL
$22.8 - $33.93 $57,159 - $85,062
-2,507 Reduced 16.55%
12,637 $364,000
Q3 2018

Nov 14, 2018

SELL
$29.75 - $43.08 $2,945 - $4,264
-99 Reduced 0.65%
15,144 $551,000
Q2 2018

Aug 13, 2018

BUY
$21.96 - $39.94 $22,003 - $40,019
1,002 Added 7.04%
15,243 $576,000
Q1 2018

May 14, 2018

SELL
$17.1 - $26.61 $40,236 - $62,613
-2,353 Reduced 14.18%
14,241 $335,000
Q4 2017

Feb 14, 2018

BUY
$9.47 - $19.59 $157,145 - $325,076
16,594
16,594 $325,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $736M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.